Metformin started early for gestational diabetes in pregnancy
Tests metformin added to diet and lifestyle in pregnant women with gestational diabetes.
Key facts
- Who runs it
- Bethesda Diabetes Research Center
- Where
- Netherlands7 sites in 1 countryChoose a country to see its sites
- Registry title
- Pregnancy Outcomes: Effects of Metformin Study (POEM Study)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 500 people, planned
- Started
- 26 Nov 2019
- Expected to end
- Dec 2043
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metformin TEVA 850 mg
- Record updated
- 10 February 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with diabetes that started in pregnancy (gestational diabetes). They will get metformin on top of usual care, or usual care alone.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Gestational diabetes: fasting blood sugar above 5,3 mMol and/or blood sugar above 7,8 mMol two hours after drinking 75 gram glucose. Pregnancy must be 16 to 32 weeks along at the start.
- Earlier treatment
- No metformin earlier in this pregnancy. No long-term corticosteroid treatment. No past weight-loss (bariatric) surgery.
- Biomarker or test result
- HbA1c (long-term blood sugar test) at the start of 48 mmol/mol (6.5% Hb) or lower.
Main reasons for not taking part
- Diabetes before this pregnancy, except earlier gestational diabetes
- Twins or more babies, broken waters, or a severe birth defect in the baby
- Kidney disease with GFR below 45 ml/min/1.73m2, or protein in the urine above 35 mg/mmol
- Cancer in the last 5 years (except non-melanoma skin cancer), or chronic liver disease
- Cannot read or understand Dutch, or severe pregnancy vomiting (hyperemesis gravidarum)
This trial only enrols pregnant participants. The registry sentence this rests on: * Pregnant women with GDM defined as a Fasting Plasma Glucose (FPG) > 5,3 mMol and/or an Oral Glucose Tolerance test (OGTT) with a Plasma glucose (PG) > 7,8 mMol, two hours after the oral intake of 75 gram glucose
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Pregnant women with GDM defined as a Fasting Plasma Glucose (FPG) > 5,3 mMol and/or an Oral Glucose Tolerance test (OGTT) with a Plasma glucose (PG) > 7,8 mMol, two hours after the oral intake of 75 gram glucose
- Written informed consent
- Age 18-45 years
- Gestational age at inclusion 16-32 weeks
- Glycohemoglobin test (HbA1c) at inclusion ≤ 48 mmol/mol (6.5% Hb)
Who cannot take part
- Diabetes mellitus before pregnancy, except previous GDM
- Chronic treatment with corticosteroids
- Bariatric surgery in medical history
- Malignancy during the last 5 years before inclusion, except non-melanoma skin cancer
- Psychiatric and/or mood disorder potentially affecting compliance of treatment
- Chronic pulmonary failure with hypoxia
- Significantly uncontrolled hypertension - Systolic blood pressure (SBP) > 160 mm Hg despite medical treatment
- Severe foetal anomaly at inclusion - like major neural tube and/or cardiac malformation
- Proteinuria: Urine Albumin-to-Creatinine Ratio (UACR) > 35 mg/mmol at screening
- Chronic liver disease and/or Alanine aminotransferase aspartate transaminase (ASAT) and/or Alanine aminotransferase (ALAT) > 3x Upper Limit of Normal (ULN)
- Chronic renal failure with a Glomerular filtration rate (GFR) < 45 ml/min/1.73m2
- Intolerance for metformin and/or earlier use of metformin in this pregnancy
- Membership of the POEM study group
- Ruptured membranes
- Multiple pregnancy
- Inability to understand or read the Dutch language
- Hyperemesis gravidarum
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
One approach to prevent the rising burden of diabetes is to address the issue of gestational diabetes mellitus (GDM). GDM has a growing prevalence up to 5-10% (and even higher in specific subgroups), with a pregnant population becoming older and more obese worldwide. GDM increases the risks of complications during pregnancy, at delivery and on the longer term, like type 2 diabetes (T2D) and persistent obesity, in mother and child. Moreover, insulin added to diet as the standard care for GDM has disadvantages for mother (maintenance of hyperinsulinaemia, increasing weight and blood pressure) and child (macrosomia, hypoglycaemia) with related adverse pregnancy outcomes. Metformin, as an insulin sensitizer targeting the cause of GDM, may have essential benefits, as suggested by observational studies. However, RCTs with metformin (early positioned in the treatment of GDM) are still lacking. The POEM study is the first Randomized controlled trial (RCT) in GDM to test the hypothesis that metformin, early given from the start of the diagnosis GDM, on top of diet and lifestyle improves clinically relevant pregnancy outcomes in mother and child during pregnancy, at delivery and on the longer term - up to 20 years after birth.
The 2 groups in the trial
- Metformin on top of usual careExisting treatment, for comparison
Metformin TEVA 850 mg (1-3 times daily) added to usual care from start of the diagnosis GDM. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed. Intervention: metformin TEVA 850 mg (1-3 times daily) on top of usual care.
Treatment: Metformin TEVA 850 mg
- Usual careNo study treatment, for comparison
Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed. Intervention: usual care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Pregnancy Outcomes: Effects of Metformin Study (POEM Study), a Long Term Randomized Controlled Study in Gestational Diabetes
- Plain-language title
- Metformin started early for gestational diabetes in pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT02947503, who can take part
- Publications
- Record updated
- 10 February 2022